About Kansas Bioscience Authority
Kansas Bioscience Authority is a venture capital firm founded in 2004. It is primarily based out of Olathe, United States. As of May 2015, Kansas Bioscience Authority has invested in 12 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Food and Agriculture Tech and HealthTech. Most recently it participated in the $***** Series A round of Flow Forward Medical Overall, Kansas Bioscience Authority portfolio has seen 4 acquisitions, namely Aratana Therapeutics, Oncimmune and Flow Forward Medical. A lot of funds co-invest with Kansas Bioscience Authority, with names like Cultivian Sandbox sharing a substantial percentage of its portfolio. Kansas Bioscience Authority has team of 1 people.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 3 more
Portfolio Acquisitions
Portfolio Soonicorns
Kansas Bioscience Authority's List of Top Investments
Kansas Bioscience Authority has a portfolio of 12 companies. Their most notable investments are in Health Outcomes Sciences and Aratana Therapeutics.Their portfolio spans across and United States. They have invested in Life Sciences, Food and Agriculture Tech, HealthTech and 5 other sectors, across stages such as Series A, Seed and 3 more. Here is the list of top investments by Kansas Bioscience Authority:
Aratana Therapeutics is a developer of pet therapeutics. It has drugs in the development stage to ease the ongoing pain and inflammation of osteoarthritis or degenerative joint disease in pets. Also has medicines in development to treat inappetence, cancer, & viral infections in pets (dogs & cats).
Key facts about Aratana Therapeutics
- Founded Year: 2010
- Location: United States
- Stage: Acquired
- Total Funding till date: $47M
- Employee Count: 16 as on Aug 31, 2026
- Investors: Square 1 Bank, Middleland Capital and 9 Others
- Latest Funding Round: Conventional Debt, Oct 16, 2015, $*****
- Highlight: Acquired
On-farm diagnostics for precise animal care, increased profits, and reduced antibiotics. The company provides livestock producers with actionable information through rapid, on-farm diagnostics, enabling informed management and treatment decisions. By offering accurate, onsite disease prediction and detection, producers can deliver more precise animal care and meet the growing global demand for quality protein. The focus is on researching, developing, and commercializing reliable, on-farm diagnostic tests. These diagnostic offerings empower real-time management decisions that increase productivity, prevent losses, improve animal welfare, and protect the food supply. The company is committed to the future of agriculture by increasing production and quality, enabling better animal health decisions, and ensuring more precise use of antibiotics.
Key facts about Advanced Animal Diagnostics
- Founded Year: 2001
- Location: Morrisville (United States)
- Stage: Series C
- Total Funding till date: $40.5M
- Employee Count: 31 as on Sep 30, 2026
- Investors: PavLyfe, Middleland Capital and 11 Others
- Latest Funding Round: Series C, May 11, 2021, $*****
- Highlight: Editors' Pick
3. Oncimmune
Immunodiagnostics company developing biomarker platforms for cancer and immune diseases. It leverages its proprietary ImmunoINSIGHTS platform, which uses large-scale autoantibody profiling and immune system analysis to generate actionable insights for drug development and patient stratification. Its technology enables pharmaceutical and biotechnology partners to identify disease-specific immune signatures, supporting earlier diagnosis, improved therapy development, and more precise treatment selection.
Key facts about Oncimmune
- Founded Year: 2006
- Location: Cambridge (United States)
- Stage: Acquired
- Employee Count: 34 as on Jul 31, 2026
- Investors: IPF Partners, WG Partners and 9 Others
- Latest Funding Round: Post IPO, Oct 21, 2024, $*****
- Highlight: Acquired
_1525749470656.png?format=webp&height=120&width=120){kind=logo}
Manufacturer of biobased plastics and biocomposite pellets. Its products include wood-plastic composites, starch biocomposites, biodegradable composites and compostable elastomers. Its product Terratek is a line of biobased compostable material that is claimed to replace plastics. The company also claims that its products withstand high temperature and will replace 65 percent of plastic products with renewable materials.
Key facts about Green Dot Bioplastics
- Founded Year: 2011
- Location: Emporia (United States)
- Stage: Series A
- Total Funding till date: $12.6M
- Employee Count: 14 as on Sep 30, 2026
- Investors: Open Prairie Ventures, Fulcrum Global Capital and 4 Others
- Latest Funding Round: Series A, Nov 10, 2021, $*****
- Highlight: Editors' Pick
Provider of a wearable medical device to facilitate vascular access in hemodialysis patients. The company is developing the Arteriovenous Fistula Eligibility (AFE) System, a temporary, wearable medical device that rapidly and permanently dilates peripheral veins. The company claims that it will enable(make eligible) nearly all hemodialysis patients to quickly establish a high-quality, reliable arteriovenous fistula for vascular access.
Key facts about Flow Forward Medical
- Founded Year: 2010
- Location: Olathe (United States)
- Stage: Acquired
- Total Funding till date: $11.2M
- Investors: Mid America Angels, Open Prairie Ventures and 2 Others
- Latest Funding Round: Series A, May 28, 2020, $*****
- Highlight: Acquired
Kansas Bioscience Authority's Investments by Stage
Kansas Bioscience Authority has made 6 investments in Series A stage with an average round size of $7.69M, 2 investments in Seed stage with an average round size of $1.25M, 1 investment in Grant (prize money) stage with an average round size of $200K, 1 investment in Series C stage with an average round size of $1.5M and 1 investment in Venture Debt stage with an average round size of $700K.Stage of entry | No. of Investments |
|---|---|
Series A | 6 |
Seed | 2 |
Grant (prize money) | 1 |
Series C | 1 |
Venture Debt | 1 |
Note: We have considered here, only first round of investments
Kansas Bioscience Authority's Investments by Sector
Kansas Bioscience Authority has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Enterprise Applications, Food and Agriculture Tech and Chemicals and Materials Tech. Notably, it has invested in 11 Enterprise (B2B) companies, 11 Tech companies, 3 Tech hardware companies and at least 2 companies focusing on Social impact.Sector | No. of Investments |
|---|---|
Life Sciences | 5 |
HealthTech | 3 |
Enterprise Applications | 2 |
Food and Agriculture Tech | 2 |
Chemicals and Materials Tech | 1 |
Others | 5 |
Note: We have considered here, only first round of investments
Kansas Bioscience Authority's Investments by Geography
Kansas Bioscience Authority has made most investments in United States (11).Kansas Bioscience Authority's recent investments
Kansas Bioscience Authority has not made any investment in 2026 so far.Here are the most recent investments by Kansas Bioscience Authority:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 18, 2015 | United States | Series A | 6932 | - | |
Apr 27, 2015 | United States | Series A | 2741 | [+1] | |
Mar 26, 2015 | United States | Series A | 7057 | ||
Feb 23, 2015 | United States | Series A | 2443 | - | |
Dec 08, 2014 | United States | Series C | 4975 | [+4] |
Acquired companies in Kansas Bioscience Authority's Portfolio
4 companies from Kansas Bioscience Authority's portfolio have been acquired. The most recent acquisition was Oncimmune in Jul 2025 by Alden Scientific for $*****.Here are Kansas Bioscience Authority's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 14, 2025 | - | - | 7086 | |
Feb 24, 2021 | Mar 10, 2014 | Series A | 5066 | |
Jul 23, 2020 | May 18, 2015 | Series A | 6241 | |
Apr 26, 2019 | Jan 07, 2011 | Series A | 8606 |
Team profile of Kansas Bioscience Authority
Kansas Bioscience Authority has a team of 1 member located in United States. Kansas Bioscience Authority's team does not sit on the board of any company as of now.Co-investors of Kansas Bioscience Authority
Over the past 18 years, 31 investors have co-invested in Kansas Bioscience Authority's portfolio companies. This includes only funds.
- Invested before Kansas Bioscience Authority: Intersouth Partners, Novartis Venture Fund and 2 others have invested in rounds before Kansas Bioscience Authority. There is 1 company where Intersouth Partners has invested before Kansas Bioscience Authority and 1 company where Novartis Venture Fund has invested before Kansas Bioscience Authority.
- Top Co-investors of Kansas Bioscience Authority: 8 investors entered a company along with Kansas Bioscience Authority. These include investors like Cultivian Sandbox (2 companies).
- Invested after Kansas Bioscience Authority: A total of 19 investors have invested in Kansas Bioscience Authority's portfolio after their investments. Top Investors include Mid America Angels (2 companies), Kauffman Foundation (1 company) and Square 1 Bank (1 company).
Recent News related to Kansas Bioscience Authority
•
Flow Forward Medical raises additional $1.3MStartland News•May 18, 2015•Flow Forward Medical, Kansas Bioscience Authority
•
Canine Cancer Lab TVAX Gets $2 Million - Veterinary Practice NewsVeterinary Practice News•Mar 26, 2015•Elias Animal Health, Mid America Angels, Kansas Bioscience Authority
•
Metactive Closes $2 Million of Additional Series A Financing and Appoints David Ferrera to the Board of Directors | Business WireBusiness Wire•Feb 23, 2015•Metactive Medical, Kansas Bioscience Authority
•
Advanced Animal Diagnostics Closes $15 Million in Oversubscribed Series C FundingPR Newswire•Dec 08, 2014•Advanced Animal Diagnostics, Advanced Animal Diagnostics, Cultivian Sandbox, Kansas Bioscience Authority and 6 others
•
Aratana Therapeutics Closes $20 Series A Financing |FinSMEsFinSMEs•Jan 07, 2011•Aratana Therapeutics, MPM BioImpact, Avalon Ventures, Kansas Bioscience Authority and 1 other
•
Aratana Inks $20M For Animal Health - PE HubPE Hub•Jan 07, 2011•Aratana Therapeutics, MPM BioImpact, Avalon Ventures, Kansas Bioscience Authority and 1 other
•
VasoGenix Raises $400K - PE HubPE Hub•Jan 30, 2009•VasoGenix Pharmaceuticals, Kansas Bioscience Authority
•
•
•
Metactive Closes $2 Million of Additional Series A FinancingKansas Bioscience Authority•Metactive Medical, Kansas Bioscience Authority
